This includes its effectiveness in breast cancer cells representing tumor phenotypes such as Estrogen Receptor-positive (ER +), Human Epidermal Growth Factor Receptor Type 2 (HER-2) enriched, and Triple Negative (TN), which lacks expression of ER, Progesterone Receptor (PR), and HER-2 (Table 2). This evidence concerns the gene ESR1 and breast carcinoma.